Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bioregenx (BRGX) Total Current Liabilities (2021 - 2025)

Bioregenx (BRGX) has 5 years of Total Current Liabilities data on record, last reported at $3.9 million in Q3 2025.

  • For Q3 2025, Total Current Liabilities rose 11.81% year-over-year to $3.9 million; the TTM value through Sep 2025 reached $3.9 million, up 11.81%, while the annual FY2024 figure was $3.6 million, 30.35% up from the prior year.
  • Total Current Liabilities reached $3.9 million in Q3 2025 per BRGX's latest filing, roughly flat from $3.9 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $3.9 million in Q3 2025 and bottomed at $14159.0 in Q4 2021.
  • Average Total Current Liabilities over 5 years is $2.2 million, with a median of $3.4 million recorded in 2024.
  • Peak YoY movement for Total Current Liabilities: surged 8553.83% in 2024, then grew 11.81% in 2025.
  • A 5-year view of Total Current Liabilities shows it stood at $14159.0 in 2021, then skyrocketed by 358.22% to $64880.0 in 2022, then skyrocketed by 4195.9% to $2.8 million in 2023, then soared by 30.35% to $3.6 million in 2024, then rose by 8.27% to $3.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Current Liabilities were $3.9 million in Q3 2025, $3.9 million in Q2 2025, and $3.8 million in Q1 2025.